ACEGEN: Reinforcement learning of generative chemical agents for drug discoveryAlbert Bou, Morgan Thomas, Sebastian Dittert et al.
In recent years, reinforcement learning (RL) has emerged as a valuable tool in drug design, offering the potential to propose and optimize molecules with desired properties. However, striking a balance between capabilities, flexibility, reliability, and efficiency remains challenging due to the complexity of advanced RL algorithms and the significant reliance on specialized code. In this work, we introduce ACEGEN, a comprehensive and streamlined toolkit tailored for generative drug design, built using TorchRL, a modern RL library that offers thoroughly tested reusable components. We validate ACEGEN by benchmarking against other published generative modeling algorithms and show comparable or improved performance. We also show examples of ACEGEN applied in multiple drug discovery case studies. ACEGEN is accessible at \url{https://github.com/acellera/acegen-open} and available for use under the MIT license.
8.7LGOct 17, 2022
A Transformer-based Generative Model for De Novo Molecular DesignWenlu Wang, Ye Wang, Honggang Zhao et al.
In the scope of drug discovery, the molecular design aims to identify novel compounds from the chemical space where the potential drug-like molecules are estimated to be in the order of 10^60 - 10^100. Since this search task is computationally intractable due to the unbounded search space, deep learning draws a lot of attention as a new way of generating unseen molecules. As we seek compounds with specific target proteins, we propose a Transformer-based deep model for de novo target-specific molecular design. The proposed method is capable of generating both drug-like compounds (without specified targets) and target-specific compounds. The latter are generated by enforcing different keys and values of the multi-head attention for each target. In this way, we allow the generation of SMILES strings to be conditional on the specified target. Experimental results demonstrate that our method is capable of generating both valid drug-like compounds and target-specific compounds. Moreover, the sampled compounds from conditional model largely occupy the real target-specific molecules' chemical space and also cover a significant fraction of novel compounds.